Michael Hahne

Michael Hahne

Auto-generated profile, based on publicly available information

Michael Hahne

IGMM - Institut de Genetique Moleculaire de Montpellier

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 September 2021 in Cancers
Verified
Journal Article
Open access
PDF file
PAParis Jabeen Asif
Paris Jabeen Asif
CLCiro Longobardi
Ciro Longobardi
MHMichael Hahne
Michael Hahne
JMJan Paul Medema
Jan Paul Medema
Cancer-associated fibroblasts (CAFs) play a key role in cancer progression by contributing to extracellular matrix (ECM) deposition and remodeling, extensive crosstalk with cancer cells, epithelial-to-mesenchymal transition (EMT), invasion, metastasis, and therapy resistance. As metastasis is a main reason for cancer-related deaths, it is crucial to understand the role of CAFs in this process. Colorectal cancer (CRC) is a heterogeneous disease and lethality is especially common in a subtype of CRC with high stromal infiltration. A key component of stroma is cancer-associated fibroblasts (CAFs). To provide new perspectives for research on CAFs and CAF-targeted therapeutics, especially in CRC, we discuss the mechanisms, crosstalk, and functions involved in CAF-mediated cancer invasion, metastasis, and protection. This summary can serve as a framework for future studies elucidating these roles of CAFs.

1 September 2014 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
CRCecilia Rocha
Cecilia Rocha
LPLaura Papon
Laura Papon
WCWulfran Cacheux
Wulfran Cacheux
PSPatricia Marques Sousa
Patricia Marques Sousa
VLValeria Lascano
Valeria Lascano
CJCarsten Janke
Carsten Janke
TTLL3 and TTLL8 are tubulin glycine ligases catalyzing posttranslational glycylation of microtubules. We show here for the first time that these enzymes are required for robust formation of primary cilia. We further discover the existence of primary cilia in colon and demonstrate that TTLL3 is the only glycylase in this organ. As a consequence, colon epithelium shows a reduced number of primary cilia accompanied by an increased rate of cell division in TTLL3‐knockout mice. Strikingly, higher proliferation is compensated by faster tissue turnover in normal colon. In a mouse model for tumorigenesis, lack of TTLL3 strongly promotes tumor development. We further demonstrate that decreased levels of TTLL3 expression are linked to the development of human colorectal carcinomas. Thus, we have uncovered a novel role for tubulin glycylation in primary cilia maintenance, which controls cell proliferation of colon epithelial cells and plays an essential role in colon cancer development. ![][1] This study reports first evidence for tubulin glycylation to affect the establishment and maintenance of primary cilia. Functional abrogation of tubulin glycine ligases impacts cell proliferation and tumor onset. The EMBO Journal (2014) 33: 2247–2260 [1]: pending:yes

22 October 2018 in EMBO Reports
Verified
Journal Article
Open access
PDF file
TEThibaut Eguether
Thibaut Eguether
MHMichael Hahne
Michael Hahne
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

26 July 2011 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
FCFlavia Calmon-Hamaty
Flavia Calmon-Hamaty
BCBernard Combe
Bernard Combe
MHMichael Hahne
Michael Hahne
JMJacques Morel
Jacques Morel
Rheumatoid arthritis (RA) is a chronic inflammatory disease affecting synovial joints. Therapies blocking tumor necrosis factor-alpha (TNFα) are now routinely used in the management of RA. However, a significant number of patients with RA do not respond or develop resistance to anti-TNF therapies, and the participation of other cytokines in RA pathogenesis has been reported as well. Lymphotoxin alpha (LTα) is the closest homolog to TNFα and has been implicated in inflammation and autoimmunity since its original description in 1968. In spite of that, little is known about the role of LTα in RA or the potential of blocking this cytokine as an alternative therapeutic approach. In this review, we aim to summarize the general features of LTα and what is currently known about its participation in RA.

7 July 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
KCKarim Chebli
Karim Chebli
LPLaura Papon
Laura Papon
CPConception Paul
Conception Paul
AGAude Garcel
Aude Garcel
NCNoëlie Campos
Noëlie Campos
JTJamal Tazi
Jamal Tazi
The progression of human immunodeficiency virus (HIV) is associated with mucosal damage in the gastrointestinal (GI) tract. This damage enables bacterial translocation from the gut and leads to subsequent inflammation. Dextran sulfate sodium (DSS-exposure) is an established animal model for experimental colitis that was recently shown to recapitulate the link between GI-tract damage and pathogenic features of SIV infection. The current study tested the protective properties of ABX464, a first-in-class anti-HIV drug candidate currently in phase II clinical trials. ABX464 treatment strongly attenuated DSS-induced colitis in mice and produced a long-term protection against prolonged DSS-exposure after drug cessation. Consistently, ABX464 reduced the colonic production of the inflammatory cytokines IL-6 and TNFα as well as that of the chemoattractant MCP-1. However, RNA profiling analysis revealed the capacity of ABX464 to induce the expression of IL-22, a cytokine involved in colitis tissue repair, both in DSS-treated mice and in LPS-stimulated bone marrow-derived macrophages. Importantly, anti-IL-22 antibodies significantly reduced the protective effect of ABX464 on colitis in DSS-treated mice. Because reduced IL-22 production in the gut mucosa is an established factor of HIV and DSS-induced immunopathogenesis, our data suggest that the anti-inflammatory properties of ABX464 warrant exploration in both HIV and inflammatory ulcerative colitis (UC) disease.

15 February 2021 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
YGYuchen Guo
Yuchen Guo
MGMonica Gabola
Monica Gabola
Rossano LattanzioRossano Lattanzio
Rossano Lattanzio
PPPaul Paul
Paul Paul
VPValérie Pinet
Valérie Pinet
MHMichael Hahne
Michael Hahne
To clarify the function of cyclin A2 in colon homeostasis and colorectal cancer (CRC), we generated mice deficient for cyclin A2 in colonic epithelial cells (CECs). Colons of these mice displayed architectural changes in the mucosa and signs of inflammation, as well as increased proliferation of CECs associated with the appearance of low- and high-grade dysplasias. The main initial events triggering those alterations in cyclin A2–deficient CECs appeared to be abnormal mitoses and DNA damage. Cyclin A2 deletion in CECs promoted the development of dysplasia and adenocarcinomas in a murine colitis–associated cancer model. We next explored the status of cyclin A2 expression in clinical CRC samples at the mRNA and protein levels and found higher expression in tumors of patients with stage 1 or 2 CRC compared with those of patients with stage 3 or 4 CRC. A meta-analysis of 11 transcriptome data sets comprising 2239 primary CRC tumors revealed different expression levels of CCNA2 (the mRNA coding for cyclin A2) among the CRC tumor subtypes, with the highest expression detected in consensus molecular subtype 1 (CMS1) and the lowest in CMS4 tumors. Moreover, we found high expression of CCNA2 to be a new, independent prognosis factor for CRC tumors.